Clinical Trials Logo

Glaucoma, Open-Angle clinical trials

View clinical trials related to Glaucoma, Open-Angle.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 5

NCT ID: NCT01711177 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma

Start date: October 2012
Phase: N/A
Study type: Interventional

Glaucoma is the second leading cause of blindness among seniors in Canada. It is often associated with an elevated intraocular pressure (IOP), but its exact mechanism is still largely unknown. Some studies have shown a link between glaucoma and changes in the amount of oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular veins among three different groups using a spectrophotometer. This instrument is linked to a camera and can measure the quantity of oxygen in the veins using different characteristics of the blood inside. The groups of the study are: patients without glaucoma, patients suspected of glaucoma and patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost 0.004%, will only be administered to the groups suspected or diagnosed with glaucoma. Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten patients will be recruited into each group for a total of 30 patients in this study. All patients for the suspected or diagnosed groups will be recruited from the Jewish General Hospital. Subsequently all testing will be done at the École d'optométrie, Université de Montréal

NCT ID: NCT01346904 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

a 3.0T Magnetic Resonance Imaging Study

Start date: May 2011
Phase: N/A
Study type: Observational

Glaucomatous damage not only occurred to retinal ganglion cells in the eyes, but went across optic nerves, visual chiasm, lateral geniculate nucleus (LGN) and finally the visual cortex; the neural degenerations could be identified through the whole visual tract, which suggests the central nerve system may play a vital role in the progression of glaucoma. The investigators used MRI to investigate changes of visual pathway in vivo.

NCT ID: NCT00739154 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Protective Effect of Phenytoin on Glaucoma

Start date: November 2008
Phase: N/A
Study type: Observational

since glaucoma is considered an optic neuropathy, new treatments for glaucoma are being continuously investigated, including neuroprotection. Previous studies implied that phenytoin, a potent anti-convulsive drug, has a neuroprotective role, and Na+ channels blockage was suggested as a possible mechanism. This study predicts that glaucoma patients taking Phenytoin will have a less advanced glaucoma as compared to patients not taking the drug. Glaucoma severity will be determined by visual acuity, visual fields, optic disc cupping and nerve fiber layer thickness